Form 4: Arvinas CMO Granted Significant Equity Awards

Arvinas Chief Medical Officer Noah Berkowitz received substantial equity awards, including restricted stock units and stock options, as part of the company's incentive plan.

Summary

• Noah Berkowitz, Chief Medical Officer of Arvinas, Inc. (ARVN), was granted 45,000 Restricted Stock Units (RSUs) on February 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration.
• The RSUs will vest over four years, with one-quarter vesting on February 26, 2027, 2028, 2029, and 2030, subject to continued service.
• Additionally, Mr. Berkowitz was granted 67,000 stock options on February 26, 2026, with an exercise price of $13.38 per share.
• The stock options will vest over four years, with one-quarter vesting on February 26, 2027, and the remainder vesting in equal monthly installments through February 26, 2030, subject to continued service.
• Following these transactions, Mr. Berkowitz beneficially owns 208,938 shares of common stock and 67,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with long-term shareholder interests and the retention of key management. It is a routine compensation event rather than a significant market-moving announcement.

Positives

• The equity grants align the Chief Medical Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The awards are part of the company's 2018 Stock Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedules for both the RSUs and stock options extend through February 2030, indicating an expectation of continued service from the Chief Medical Officer and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity grants, such as RSUs and stock options, are a standard and prevalent form of executive compensation in the biotechnology industry. These awards are crucial for attracting, retaining, and motivating key talent in a highly competitive sector, aligning executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The structure of these equity grants, including a four-year vesting schedule, is consistent with common practices for executive compensation in the biotechnology and pharmaceutical sectors, similar to grants observed at companies like Moderna or BioNTech for their senior executives.
• The use of both RSUs (which provide value even if the stock price declines) and stock options (which incentivize stock price appreciation) is a balanced approach often seen in growth-oriented biotech firms to manage risk and reward for executives.

Stakeholder Impact

• Shareholders: The grants align executive interests with long-term shareholder value, potentially leading to better performance. However, they also represent future dilution as shares are issued upon vesting and exercise.
• Employees (specifically Noah Berkowitz): Provides significant long-term incentive and compensation, enhancing retention and motivation.

Next Steps

• The RSUs and stock options will vest according to their respective schedules, contingent on Noah Berkowitz's continued service with Arvinas, Inc.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a key executive, which is a positive for management alignment and retention but does not provide new information to alter an investment thesis or warrant a change in stock recommendation based solely on this filing.

Keywords

ARVINAS, ARVN, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology